Top

Current Heart Failure Reports

Published in:

Open Access 01-08-2017 | Comorbidities of Heart Failure (C Angermann & F Edelmann, Section Editors)

From Inflammation to Fibrosis—Molecular and Cellular Mechanisms of Myocardial Tissue Remodelling and Perspectives on Differential Treatment Opportunities

Authors: Navin Suthahar, Wouter C. Meijers, Herman H.W. Silljé, Rudolf A. de Boer

Published in: Current Heart Failure Reports | Issue 4/2017

Abstract

Purpose of Review

In this review, we highlight the most important cellular and molecular mechanisms that contribute to cardiac inflammation and fibrosis. We also discuss the interplay between inflammation and fibrosis in various precursors of heart failure (HF) and how such mechanisms can contribute to myocardial tissue remodelling and development of HF.

Recent Findings

Recently, many research articles attempt to elucidate different aspects of the interplay between inflammation and fibrosis. Cardiac inflammation and fibrosis are major pathophysiological mechanisms operating in the failing heart, regardless of HF aetiology. Currently, novel therapeutic options are available or are being developed to treat HF and these are discussed in this review.

Summary

A progressive disease needs an aggressive management; however, existing therapies against HF are insufficient. There is a dynamic interplay between inflammation and fibrosis in various precursors of HF such as myocardial infarction (MI), myocarditis and hypertension, and also in HF itself. There is an urgent need to identify novel therapeutic targets and develop advanced therapeutic strategies to combat the syndrome of HF. Understanding and describing the elements of the inflammatory and fibrotic pathways are essential, and specific drugs that target these pathways need to be evaluated.

Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011;8:30–41. doi:10.1038/nrcardio.2010.165.PubMedCrossRef

Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66:271–89. doi:10.3322/caac.21349.PubMedCrossRef

Giamouzis G, Kalogeropoulos A, Georgiopoulou V, Laskar S, Smith AL, Dunbar S, et al. Hospitalization epidemic in patients with heart failure: risk factors, risk prediction, knowledge gaps, and future directions. J Card Fail. 2011;17:54–75. doi:10.1016/j.cardfail.2010.08.010.PubMedCrossRef

Kong P, Christia P, Frangogiannis NG. The pathogenesis of cardiac fibrosis. Cell Mol Life Sci. 2014;71:549–74. doi:10.1007/s00018-013-1349-6.PubMedCrossRef

Lee SB, Kalluri R. Mechanistic connection between inflammation and fibrosis. Kidney Int Suppl. 2010;100:S22–6. doi:10.1038/ki.2010.418.CrossRef

Serhan CN, Brain SD, Buckley CD, Gilroy DW, Haslett C, O’Neill LAJ, et al. Resolution of inflammation: state of the art, definitions and terms. FASEB J. 2007;21:325–32. doi:10.1096/fj.06-7227rev.PubMedPubMedCentralCrossRef

Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med. 2012;18:1028–40. doi:10.1038/nm.2807.PubMedPubMedCentralCrossRef

Wilhelm DL. Mechanisms responsible for increased vascular permeability in acute inflammation. Agents Actions. 1973;3:297–306. doi:10.1007/BF01986484.PubMedCrossRef

Zheng W, Li R, Pan H, He D, Xu R, Guo TB, et al. Role of osteopontin in induction of monocyte chemoattractant protein 1 and macrophage inflammatory protein 1beta through the NF-kappaB and MAPK pathways in rheumatoid arthritis. Arthritis Rheum. 2009;60:1957–65. doi:10.1002/art.24625.PubMedCrossRef

10.

Wight TN, Kang I, Merrilees MJ. Versican and the control of inflammation. Matrix Biol. 2014;35:152–61. doi:10.1016/j.matbio.2014.01.015.PubMedPubMedCentralCrossRef

11.

Petrey AC, de la Motte CA. Hyaluronan, a crucial regulator of inflammation. Front Immunol. 2014;5:101. doi:10.3389/fimmu.2014.00101.PubMedPubMedCentralCrossRef

12.

Neumann A, Schinzel R, Palm D, Riederer P, Münch G. High molecular weight hyaluronic acid inhibits advanced glycation endproduct-induced NF-kappaB activation and cytokine expression. FEBS Lett. 1999;453:283–7. doi:10.1016/S0014-5793(99)00731-0.PubMedCrossRef

13.

Litwiniuk M, Krejner A, Speyrer MS, Gauto AR, Grzela T. Hyaluronic acid in inflammation and tissue regeneration. Wounds a Compend Clin Res Pract. 2016;28:78–88. doi:10.1124/dmd.107.016501.CYP3A4-Mediated.

14.

Rayahin JE, Buhrman JS, Zhang Y, Koh TJ, Gemeinhart RA. High and low molecular weight hyaluronic acid differentially influence macrophage activation. ACS Biomater Sci Eng. 2015;1:481–93. doi:10.1021/acsbiomaterials.5b00181.PubMedPubMedCentralCrossRef

15.

•• Ortega-Gómez A, Perretti M, Soehnlein O. Resolution of inflammation: an integrated view. EMBO Mol Med. 2013;5:661–74. doi:10.1002/emmm.201202382. Authoritative review on the resolution of inflammation and its consequences, including the development of fibrosis.

16.

Serhan CN, Chiang N, Dalli J. The resolution code of acute inflammation: novel pro-resolving lipid mediators in resolution. Semin Immunol. 2015;27:200–15. doi:10.1016/j.smim.2015.03.004.PubMedPubMedCentralCrossRef

17.

Buckley CD, Gilroy DW, Serhan CN. Proresolving lipid mediators and mechanisms in the resolution of acute inflammation. Immunity. 2014;40:315–27. doi:10.1016/j.immuni.2014.02.009.PubMedPubMedCentralCrossRef

18.

Fukao T, Koyasu S. PI3K and negative regulation of TLR signaling. Trends Immunol. 2003;24:358–63. doi:10.1016/S1471-4906(03)00139-X.PubMedCrossRef

19.

Liew FY, Xu D, Brint EK, O’Neill LAJ. Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol. 2005;5:446–58. doi:10.1038/nri1630.PubMedCrossRef

20.

Ueha S, Shand FHW, Matsushima K. Cellular and molecular mechanisms of chronic inflammation-associated organ fibrosis. Front Immunol. 2012;3:71. doi:10.3389/fimmu.2012.00071.PubMedPubMedCentralCrossRef

21.

Bochaton-Piallat M-L, Gabbiani G, Hinz B. The myofibroblast in wound healing and fibrosis: answered and unanswered questions. F1000Research 2016;5:752–25. doi:10.12688/f1000research.8190.1.

22.

• Krenning G, Zeisberg EM, Kalluri R. The origin of fibroblasts and mechanism of cardiac fibrosis. J Cell Physiol. 2010;225:631–7. doi:10.1002/jcp.22322. State-of-the-art review on the central role of the cardiac fibroblast in cardiac fibrosis.

23.

Newby AC. Metalloproteinase expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability. Arterioscler Thromb Vasc Biol. 2008;28:2108–14. doi:10.1161/ATVBAHA.108.173898.PubMedCrossRef

24.

Grabiec AM, Hussell T. The role of airway macrophages in apoptotic cell clearance following acute and chronic lung inflammation. Semin Immunopathol. 2016;38:409–23. doi:10.1007/s00281-016-0555-3.PubMedPubMedCentralCrossRef

25.

de Oliveira FT, Andrade PR, de Mattos Barbosa MG, Pinto TGT, Ferreira PF, Ferreira H, et al. Effect of apoptotic cell recognition on macrophage polarization and mycobacterial persistence. Infect Immun. 2014;82:3968–78. doi:10.1128/IAI.02194-14.CrossRef

26.

Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest. 1998;101:890–8. doi:10.1172/JCI1112.PubMedPubMedCentralCrossRef

27.

• MacKinnon AC, Farnworth SL, Hodkinson PS, Henderson NC, Atkinson KM, Leffler H, et al. Regulation of alternative macrophage activation by galectin-3. J Immunol. 2008;180:2650–8. doi:10.4049/jimmunol.180.4.2650. First description of the role of the pro-fibrotic protein galectin-3 on macrophage maturation towards the alternative phenotype.

28.

• Gong D, Shi W, Yi S, Chen H, Groffen J, Heisterkamp N. TGFβ signaling plays a critical role in promoting alternative macrophage activation. BMC Immunol. 2012;13:31. doi:10.1186/1471-2172-13-31. The quintessential fibrosis factor TGF-β is described as a player in alternative macrophage activation.

29.

Madsen DH, Leonard D, Masedunskas A, Moyer A, Jürgensen HJ, Peters DE, et al. M2-like macrophages are responsible for collagen degradation through a mannose receptor-mediated pathway. J Cell Biol. 2013;202:951–66. doi:10.1083/jcb.201301081.PubMedPubMedCentralCrossRef

30.

Van Linthout S, Miteva K, Tschöpe C. Crosstalk between fibroblasts and inflammatory cells. Cardiovasc Res. 2014;102:258–69. doi:10.1093/cvr/cvu062.PubMedCrossRef

31.

López B, González A, Lindner D, Westermann D, Ravassa S, Beaumont J, et al. Osteopontin-mediated myocardial fibrosis in heart failure: a role for lysyl oxidase? Cardiovasc Res. 2013;99:111–20. doi:10.1093/cvr/cvt100.PubMedCrossRef

32.

Murphy-Ullrich JE, Poczatek M. Activation of latent TGF-beta by thrombospondin-1: mechanisms and physiology. Cytokine Growth Factor Rev. 2000;11:59–69. doi:10.1016/S1359-6101(99)00029-5.PubMedCrossRef

33.

Garner OB, Baum LG. Galectin-glycan lattices regulate cell-surface glycoprotein organization and signalling. Biochem Soc Trans. 2008;36:1472–7. doi:10.1042/BST0361472.PubMedPubMedCentralCrossRef

34.

Yndestad A, Damås JK, Oie E, Ueland T, Gullestad L, Aukrust P. Systemic inflammation in heart failure—the whys and wherefores. Heart Fail Rev. 2006;11:83–92. doi:10.1007/s10741-006-9196-2.PubMedCrossRef

35.

Epelman S, Liu PP, Mann DL. Role of innate and adaptive immune mechanisms in cardiac injury and repair. Nat Rev Immunol. 2015;15:117–29. doi:10.1038/nri3800.PubMedPubMedCentralCrossRef

36.

Barin JG, Rose NR, Ciháková D. Macrophage diversity in cardiac inflammation: a review. Immunobiology. 2012;217:468–75. doi:10.1016/j.imbio.2011.06.009.PubMedCrossRef

37.

Ma F, Li Y, Jia L, Han Y, Cheng J, Li H, et al. Macrophage-stimulated cardiac fibroblast production of IL-6 is essential for TGF β/Smad activation and cardiac fibrosis induced by angiotensin II. PLoS One. 2012;7:e35144. doi:10.1371/journal.pone.0035144.PubMedPubMedCentralCrossRef

38.

Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep 2014;6:13. doi:10.12703/P6-13.

39.

• Aoyagi T, Matsui T. The cardiomyocyte as a source of cytokines in cardiac injury. J Cell Sci Ther. 2012;2011:130–4. doi:10.1016/j.pestbp.2011.02.012.Investigations. Summary of heart as a secreting organ for inflammatory cytokines.

40.

Yu X, Deng L, Wang D, Li N, Chen X, Cheng X, et al. Mechanism of TNF-α autocrine effects in hypoxic cardiomyocytes: initiated by hypoxia inducible factor 1α, presented by exosomes. J Mol Cell Cardiol. 2012;53:848–57. doi:10.1016/j.yjmcc.2012.10.002.PubMedCrossRef

41.

Wollert KC, Drexler H. The role of interleukin-6 in the failing heart. Heart Fail Rev. 2001;6:95–103. doi:10.1023/A:1011401825680.PubMedCrossRef

42.

Gabay C. Interleukin-6 and chronic inflammation. Arthritis Res Ther 2006;8 Suppl 2:S3. doi:10.1186/ar1917.

43.

Turner NA, Mughal RS, Warburton P, O’Regan DJ, Ball SG, Porter KE. Mechanism of TNFalpha-induced IL-1alpha, IL-1beta and IL-6 expression in human cardiac fibroblasts: effects of statins and thiazolidinediones. Cardiovasc Res. 2007;76:81–90. doi:10.1016/j.cardiores.2007.06.003.PubMedCrossRef

44.

•• Lindner D, Zietsch C, Tank J, Sossalla S, Fluschnik N, Hinrichs S, et al. Cardiac fibroblasts support cardiac inflammation in heart failure. Basic Res Cardiol. 2014;109:428. doi:10.1007/s00395-014-0428-7. State-of-the-art review on the central role of the cardiac fibroblast in cardiac inflammation.

45.

Wu L, Ong S, Talor MV, Barin JG, Baldeviano GC, Kass DA, et al. Cardiac fibroblasts mediate IL-17A-driven inflammatory dilated cardiomyopathy. J Exp Med. 2014;211:1449–64. doi:10.1084/jem.20132126.PubMedPubMedCentralCrossRef

46.

Ospelt C, Gay S. TLRs and chronic inflammation. Int J Biochem Cell Biol. 2010;42:495–505. doi:10.1016/j.biocel.2009.10.010.PubMedCrossRef

47.

•• Liu L, Wang Y, Cao Z-Y, Wang M-M, Liu X-M, Gao T, et al. Up-regulated TLR4 in cardiomyocytes exacerbates heart failure after long-term myocardial infarction. J Cell Mol Med. 2015;19:2728–40. doi:10.1111/jcmm.12659. Important and interesting report on the emerging role of innate immunity and toll-like receptors in cardiac remodeling.

48.

Huebener P, Schwabe RF. Regulation of wound healing and organ fibrosis by toll-like receptors. Biochim Biophys Acta. 1832;2013:1005–17. doi:10.1016/j.bbadis.2012.11.017.

49.

Takeda K, Akira S. TLR signaling pathways. Semin Immunol. 2004;16:3–9. doi:10.1016/j.smim.2003.10.003.PubMedCrossRef

50.

Coggins M, Rosenzweig A. The fire within: cardiac inflammatory signaling in health and disease. Circ Res. 2012;110:116–25. doi:10.1161/CIRCRESAHA.111.243196.PubMedCrossRef

51.

Piek A, de Boer RA, Silljé HHW. The fibrosis-cell death axis in heart failure. Heart Fail Rev. 2016;21:199–211. doi:10.1007/s10741-016-9536-9.PubMedPubMedCentralCrossRef

52.

Travers JG, Kamal FA, Robbins J, Yutzey KE, Blaxall BC. Cardiac fibrosis: the fibroblast awakens. Circ Res. 2016;118:1021–40. doi:10.1161/CIRCRESAHA.115.306565.PubMedPubMedCentralCrossRef

53.

Tian K, Liu Z, Wang J, Xu S, You T, Liu P. Sirtuin-6 inhibits cardiac fibroblasts differentiation into myofibroblasts via inactivation of nuclear factor κB signaling. Transl Res. 2015;165:374–86. doi:10.1016/j.trsl.2014.08.008.PubMedCrossRef

54.

•• Herum KM, Lunde IG, Skrbic B, Louch WE, Hasic A, Boye S, et al. Syndecan-4 is a key determinant of collagen cross-linking and passive myocardial stiffness in the pressure-overloaded heart. Cardiovasc Res. 2015;106:217–26. doi:10.1093/cvr/cvv002. The prominent role of proteoglycans and other ECM associated proteins is supported by this interesting article focusing on syndecan-4.

55.

Fujiu K, Nagai R. Fibroblast-mediated pathways in cardiac hypertrophy. J Mol Cell Cardiol. 2014;70:64–73. doi:10.1016/j.yjmcc.2014.01.013.PubMedCrossRef

56.

Fredj S, Bescond J, Louault C, Delwail A, Lecron J-C, Potreau D. Role of interleukin-6 in cardiomyocyte/cardiac fibroblast interactions during myocyte hypertrophy and fibroblast proliferation. J Cell Physiol. 2005;204:428–36. doi:10.1002/jcp.20307.PubMedCrossRef

57.

Pellman J, Zhang J, Sheikh F. Myocyte-fibroblast communication in cardiac fibrosis and arrhythmias: mechanisms and model systems. J Mol Cell Cardiol. 2016;94:22–31. doi:10.1016/j.yjmcc.2016.03.005.PubMedPubMedCentralCrossRef

58.

Falkenham A, de Antueno R, Rosin N, Betsch D, Lee TDG, Duncan R, et al. Nonclassical resident macrophages are important determinants in the development of myocardial fibrosis. Am J Pathol. 2015;185:927–42. doi:10.1016/j.ajpath.2014.11.027.PubMedCrossRef

59.

•• Moriwaki H, Stempien-Otero A, Kremen M, Cozen AE, Dichek DA. Overexpression of urokinase by macrophages or deficiency of plasminogen activator inhibitor type 1 causes cardiac fibrosis in mice. Circ Res. 2004;95:637–44. doi:10.1161/01.RES.0000141427.61023.f4. Heparin-associated proteins and urokinase have important effects in myocardial fibrosis.

60.

Carlson S, Helterline D, Asbe L, Dupras S, Minami E, Farris S, et al. Cardiac macrophages adopt profibrotic/M2 phenotype in infarcted hearts: role of urokinase plasminogen activator. J Mol Cell Cardiol. 2016;128 doi:10.1016/j.yjmcc.2016.05.016.

61.

Henri O, Pouehe C, Houssari M, Galas L, Nicol L, Edwards-Lévy F, et al. Selective stimulation of cardiac lymphangiogenesis reduces myocardial edema and fibrosis leading to improved cardiac function following myocardial infarction. Circulation. 2016;133:1484–1497; discussion 1497. doi:10.1161/CIRCULATIONAHA.115.020143.PubMedCrossRef

62.

Levick SP, Meléndez GC, Plante E, McLarty JL, Brower GL, Janicki JS. Cardiac mast cells: the centrepiece in adverse myocardial remodelling. Cardiovasc Res. 2011;89:12–9. doi:10.1093/cvr/cvq272.PubMedCrossRef

63.

Levick SP, McLarty JL, Murray DB, Freeman RM, Carver WE, Brower GL. Cardiac mast cells mediate left ventricular fibrosis in the hypertensive rat heart. Hypertens (Dallas, Tex 1979) 2009;53:1041–7. doi:10.1161/HYPERTENSIONAHA.108.123158.

64.

de Boer RA, Pinto YM, Van Veldhuisen DJ. The imbalance between oxygen demand and supply as a potential mechanism in the pathophysiology of heart failure: the role of microvascular growth and abnormalities. Microcirculation. 2003;10:113–26. doi:10.1038/sj.mn.7800188.PubMedCrossRef

65.

van der Meer P, Lipsic E, Henning RH, Boddeus K, van der Velden J, Voors AA, et al. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol. 2005;46:125–33. doi:10.1016/j.jacc.2005.03.044.PubMedCrossRef

66.

Namiuchi S, Kagaya Y, Ohta J, Shiba N, Sugi M, Oikawa M, et al. High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention. J Am Coll Cardiol. 2005;45:1406–12. doi:10.1016/j.jacc.2005.01.043.PubMedCrossRef

67.

Gogiraju R, Xu X, Bochenek ML, Steinbrecher JH, Lehnart SE, Wenzel P, et al. Endothelial p53 deletion improves angiogenesis and prevents cardiac fibrosis and heart failure induced by pressure overload in mice. J Am Heart Assoc. 2015;4:1–22. doi:10.1161/JAHA.115.001770.CrossRef

68.

Meloni M, Marchetti M, Garner K, Littlejohns B, Sala-Newby G, Xenophontos N, et al. Local inhibition of microRNA-24 improves reparative angiogenesis and left ventricle remodeling and function in mice with myocardial infarction. Mol Ther. 2013;21:1390–402. doi:10.1038/mt.2013.89.PubMedPubMedCentralCrossRef

69.

Rienks M, Papageorgiou A-P, Frangogiannis NG, Heymans S. Myocardial extracellular matrix: an ever-changing and diverse entity. Circ Res. 2014;114:872–88. doi:10.1161/CIRCRESAHA.114.302533.PubMedCrossRef

70.

Mustonen E, Ruskoaho H, Rysä J. Thrombospondins, potential drug targets for cardiovascular diseases. Basic Clin Pharmacol Toxicol. 2013;112:4–12. doi:10.1111/bcpt.12026.PubMedCrossRef

71.

Frolova EG, Sopko N, Blech L, Popovic ZB, Li J, Vasanji A, et al. Thrombospondin-4 regulates fibrosis and remodeling of the myocardium in response to pressure overload. FASEB J. 2012;26:2363–73. doi:10.1096/fj.11-190728.PubMedPubMedCentralCrossRef

72.

Zhao S, Wu H, Xia W, Chen X, Zhu S, Zhang S, et al. Periostin expression is upregulated and associated with myocardial fibrosis in human failing hearts. J Cardiol. 2014;63:373–8. doi:10.1016/j.jjcc.2013.09.013.PubMedCrossRef

73.

Westermann D, Mersmann J, Melchior A, Freudenberger T, Petrik C, Schaefer L, et al. Biglycan is required for adaptive remodeling after myocardial infarction. Circulation. 2008;117:1269–76. doi:10.1161/CIRCULATIONAHA.107.714147.PubMedCrossRef

74.

Beetz N, Rommel C, Schnick T, Neumann E, Lother A, Monroy-Ordonez EB, et al. Ablation of biglycan attenuates cardiac hypertrophy and fibrosis after left ventricular pressure overload. J Mol Cell Cardiol. 2016;101:145–55. doi:10.1016/j.yjmcc.2016.10.011.PubMedCrossRef

75.

• Jahanyar J, Joyce DL, Southard RE, Loebe M, Noon GP, Koerner MM, et al. Decorin-mediated transforming growth factor-beta inhibition ameliorates adverse cardiac remodeling. J Heart Lung Transplant. 2007;26:34–40. doi:10.1016/j.healun.2006.10.005. This article illustrates the antifibrotic properties of the extracellular matrix protein decorin in the heart. PubMedCrossRef

76.

de Boer RA, Yu L, van Veldhuisen DJ. Galectin-3 in cardiac remodeling and heart failure. Curr Heart Fail Rep. 2010;7:1–8. doi:10.1007/s11897-010-0004-x.PubMedPubMedCentralCrossRef

77.

•• Yu L, Ruifrok WPT, Meissner M, Bos EM, van Goor H, Sanjabi B, et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail. 2013;6:107–17. doi:10.1161/CIRCHEARTFAILURE.112.971168. First article describing galectin-3 as a therapeutic target in heart failure and myocardial fibrosis.

78.

Nabi IR, Shankar J, Dennis JW. The galectin lattice at a glance. J Cell Sci. 2015;128:2213–9. doi:10.1242/jcs.151159.PubMedCrossRef

79.

Talaga ML, Fan N, Fueri AL, Brown RK, Bandyopadhyay P, Dam TK. Multitasking human lectin galectin-3 interacts with sulfated glycosaminoglycans and chondroitin sulfate proteoglycans. Biochemistry. 2016;55:4541–51. doi:10.1021/acs.biochem.6b00504.PubMedCrossRef

80.

Tromp J, van der Pol A, Klip IJT, de Boer RA, Jaarsma T, van Gilst WH, et al. Fibrosis marker syndecan-1 and outcome in patients with heart failure with reduced and preserved ejection fraction. Circ Heart Fail. 2014;7:457–62. doi:10.1161/CIRCHEARTFAILURE.113.000846.PubMedCrossRef

81.

Lunde IG, Herum KM, Carlson CC, Christensen G. Syndecans in heart fibrosis. Cell Tissue Res. 2016;365:539–52. doi:10.1007/s00441-016-2454-2.PubMedCrossRef

82.

Schellings MWM, Vanhoutte D, van Almen GC, Swinnen M, Leenders JJG, Kubben N, et al. Syndecan-1 amplifies angiotensin II-induced cardiac fibrosis. Hypertens (Dallas, Tex 1979) 2010;55:249–56. doi:10.1161/HYPERTENSIONAHA.109.137885.

83.

Chan JK, Roth J, Oppenheim JJ, Tracey KJ, Vogl T, Feldmann M, et al. Alarmins: awaiting a clinical response. J Clin Invest. 2012;122:2711–9. doi:10.1172/JCI62423.PubMedPubMedCentralCrossRef

84.

Nakaya M, Watari K, Tajima M, Nakaya T, Matsuda S, Ohara H, et al. Cardiac myofibroblast engulfment of dead cells facilitates recovery after myocardial infarction. J Clin Invest. 2016:1–19. doi:10.1172/JCI83822.

85.

Frangogiannis NG. The inflammatory response in myocardial injury, repair, and remodelling. Nat Rev Cardiol. 2014;11:255–65. doi:10.1038/nrcardio.2014.28.PubMedPubMedCentralCrossRef

86.

• van Hout GPJ, Arslan F, Pasterkamp G, Hoefer IE. Targeting danger-associated molecular patterns after myocardial infarction. Expert Opin Ther Targets. 2016;20:223–39. doi:10.1517/14728222.2016.1088005. Comprehensive overview of danger-associated molecular signals in myocardial infarction and their potential utility as therapeutic targets.

87.

Nah D-Y, Rhee M-Y. The inflammatory response and cardiac repair after myocardial infarction. Korean Circ J. 2009;39:393–8. doi:10.4070/kcj.2009.39.10.393.

88.

Gabriel AS, Martinsson A, Wretlind B, Ahnve S. IL-6 levels in acute and post myocardial infarction: their relation to CRP levels, infarction size, left ventricular systolic function, and heart failure. Eur J Intern Med. 2004;15:523–8. doi:10.1016/j.ejim.2004.07.013.PubMedCrossRef

89.

Hohensinner PJ, Kaun C, Rychli K, Ben-Tal Cohen E, Kastl SP, Demyanets S, et al. Monocyte chemoattractant protein (MCP-1) is expressed in human cardiac cells and is differentially regulated by inflammatory mediators and hypoxia. FEBS Lett. 2006;580:3532–8. doi:10.1016/j.febslet.2006.05.043.PubMedCrossRef

90.

Durán WN. The double-edge sword of TNF-alpha in ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2008;295:H2221–2. doi:10.1152/ajpheart.01050.2008.PubMedPubMedCentralCrossRef

91.

• Yang M, Chen J, Zhao J, Meng M. Etanercept attenuates myocardial ischemia/reperfusion injury by decreasing inflammation and oxidative stress. PLoS One. 2014;9:e108024. doi:10.1371/journal.pone.0108024. The cytokine hypothesis was silenced after neutral RCTs with anti-TNF alpha agents, but this article and others keep the hypothesis alive.

92.

Fuchs M, Hilfiker A, Kaminski K, Hilfiker-Kleiner D, Guener Z, Klein G, et al. Role of interleukin-6 for LV remodeling and survival after experimental myocardial infarction. FASEB J. 2003;17:2118–20. doi:10.1096/fj.03-0331fje.PubMed

93.

Hartman MHT, Vreeswijk-Baudoin I, Groot HE, van de Kolk KWA, de Boer RA, Mateo Leach I, et al. Inhibition of interleukin-6 receptor in a murine model of myocardial ischemia-reperfusion. PLoS One. 2016;11:e0167195. doi:10.1371/journal.pone.0167195.PubMedPubMedCentralCrossRef

94.

Frangogiannis NG. Regulation of the inflammatory response in cardiac repair. Circ Res. 2012;110:159–73. doi:10.1161/CIRCRESAHA.111.243162.PubMedPubMedCentralCrossRef

95.

Chen W, Saxena A, Li N, Sun J, Gupta A, Lee D-W, et al. Endogenous IRAK-M attenuates postinfarction remodeling through effects on macrophages and fibroblasts. Arterioscler Thromb Vasc Biol. 2012;32:2598–608. doi:10.1161/ATVBAHA.112.300310.PubMedPubMedCentralCrossRef

96.

Meijers WC, van der Velde AR, Pascual-Figal DA, de Boer RA. Galectin-3 and post-myocardial infarction cardiac remodeling. Eur J Pharmacol. 2015;763:115–21. doi:10.1016/j.ejphar.2015.06.025.PubMedCrossRef

97.

Bujak M, Frangogiannis NG. The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res. 2007;74:184–95. doi:10.1016/j.cardiores.2006.10.002.PubMedCrossRef

98.

• Talman V, Ruskoaho H. Cardiac fibrosis in myocardial infarction—from repair and remodeling to regeneration. Cell Tissue Res. 2016;365:563–81. doi:10.1007/s00441-016-2431-9. State-of-the-art review on the complex sequelae of events postmyocardial infarction.

99.

Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation. 2000;101:2981–8. doi:10.1161/01.CIR.101.25.2981.PubMedCrossRef

100.

Corsten MF, Schroen B, Heymans S. Inflammation in viral myocarditis: friend or foe? Trends Mol Med. 2012;18:426–37. doi:10.1016/j.molmed.2012.05.005.PubMedCrossRef

101.

•• Lindner D, Li J, Savvatis K, Klingel K, Blankenberg S, Tschöpe C, et al. Cardiac fibroblasts aggravate viral myocarditis: cell specific coxsackievirus B3 replication. Mediat Inflamm. 2014;2014:519528. doi:10.1155/2014/519528. Sustained fibroblast activation may be a culprit in myocarditis.

102.

Negishi H, Osawa T, Ogami K, Ouyang X, Sakaguchi S, Koshiba R, et al. A critical link between toll-like receptor 3 and type II interferon signaling pathways in antiviral innate immunity. Proc Natl Acad Sci U S A. 2008;105:20446–51. doi:10.1073/pnas.0810372105.PubMedPubMedCentralCrossRef

103.

Badorff C, Lee GH, Lamphear BJ, Martone ME, Campbell KP, Rhoads RE, et al. Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat Med. 1999;5:320–6. doi:10.1038/6543.PubMedCrossRef

104.

Wang Q, Wehrens XHT. Connecting enterovirus infection to dystrophin dysfunction in dilated cardiomyopathy. Ann Transl Med 2016;4:S23. doi:10.21037/atm.2016.10.06.

105.

Fairweather D, Yusung S, Frisancho S, Barrett M, Gatewood S, Steele R, et al. IL-12 receptor beta 1 and toll-like receptor 4 increase IL-1 beta- and IL-18-associated myocarditis and coxsackievirus replication. J Immunol. 2003;170:4731–7. doi:10.4049/jimmunol.170.9.4731.PubMedCrossRef

106.

•• Zhao Z, Cai T-Z, Lu Y, Liu W-J, Cheng M-L, Ji Y-Q. Coxsackievirus B3 induces viral myocarditis by upregulating toll-like receptor 4 expression. Biochemistry (Mosc). 2015;80:455–62. doi:10.1134/S0006297915040094. Article on the central role of innate immunity in myocarditis.

107.

Li K, Xu W, Guo Q, Jiang Z, Wang P, Yue Y, et al. Differential macrophage polarization in male and female BALB/c mice infected with coxsackievirus B3 defines susceptibility to viral myocarditis. Circ Res. 2009;105:353–64. doi:10.1161/CIRCRESAHA.109.195230.PubMedCrossRef

108.

Schwimmbeck PL, Rohn G, Wrusch A, Schulze K, Doerner A, Kuehl U, et al. Enteroviral and immune mediated myocarditis in SCID mice. Herz. 2000;25:240–4. doi:10.1007/s000590050013.PubMedCrossRef

109.

Cihakova D, Barin JG, Afanasyeva M, Kimura M, Fairweather D, Berg M, et al. Interleukin-13 protects against experimental autoimmune myocarditis by regulating macrophage differentiation. Am J Pathol. 2008;172:1195–208. doi:10.2353/ajpath.2008.070207.PubMedPubMedCentralCrossRef

110.

Drazner MH. The progression of hypertensive heart disease. Circulation. 2011;123:327–34. doi:10.1161/CIRCULATIONAHA.108.845792.PubMedCrossRef

111.

Bleakley C, Hamilton PK, Pumb R, Harbinson M, McVeigh GE. Endothelial function in hypertension: victim or culprit? J Clin Hypertens (Greenwich). 2015;17:651–4. doi:10.1111/jch.12546.CrossRef

112.

Harvey A, Montezano AC, Lopes RA, Rios F, Touyz RM. Vascular fibrosis in aging and hypertension: molecular mechanisms and clinical implications. Can J Cardiol. 2016;32:659–68. doi:10.1016/j.cjca.2016.02.070.PubMedPubMedCentralCrossRef

113.

Díez J. Mechanisms of cardiac fibrosis in hypertension. J Clin Hypertens (Greenwich). 2007;9:546–50. doi:10.1111/j.1524-6175.2007.06626.x.CrossRef

114.

Xia Y, Lee K, Li N, Corbett D, Mendoza L, Frangogiannis NG. Characterization of the inflammatory and fibrotic response in a mouse model of cardiac pressure overload. Histochem Cell Biol. 2009;131:471–81. doi:10.1007/s00418-008-0541-5.PubMedCrossRef

115.

Azibani F, Fazal L, Chatziantoniou C, Samuel J-L, Delcayre C. Aldosterone mediates cardiac fibrosis in the setting of hypertension. Curr Hypertens Rep. 2013;15:395–400. doi:10.1007/s11906-013-0354-3.PubMedCrossRef

116.

Kovács Á, Fülöp GÁ, Kovács A, Csípő T, Bódi B, Priksz D, et al. Renin overexpression leads to increased titin-based stiffness contributing to diastolic dysfunction in hypertensive mRen2 rats. Am J Physiol Heart Circ Physiol. 2016;310:H1671–82. doi:10.1152/ajpheart.00842.2015.PubMedCrossRef

117.

Murphy AM, Wong AL, Bezuhly M. Modulation of angiotensin II signaling in the prevention of fibrosis. Fibrogenesis Tissue Repair. 2015;8:7. doi:10.1186/s13069-015-0023-z.PubMedPubMedCentralCrossRef

118.

•• González GE, Rhaleb N-E, D’Ambrosio MA, Nakagawa P, Liu Y, Leung P, et al. Deletion of interleukin-6 prevents cardiac inflammation, fibrosis and dysfunction without affecting blood pressure in angiotensin II-high salt-induced hypertension. J Hypertens. 2015;33:144–52. doi:10.1097/HJH.0000000000000358. Article providing interesting data to support a beneficial role for anti-interleukin 6 agents in heart failure.

119.

González GE, Rhaleb N-E, D’Ambrosio MA, Nakagawa P, Liao T-D, Peterson EL, et al. Cardiac-deleterious role of galectin-3 in chronic angiotensin II-induced hypertension. Am J Physiol Heart Circ Physiol. 2016;311:H1287–96. doi:10.1152/ajpheart.00096.2016.PubMedCrossRef

120.

Collins AR, Schnee J, Wang W, Kim S, Fishbein MC, Bruemmer D, et al. Osteopontin modulates angiotensin II-induced fibrosis in the intact murine heart. J Am Coll Cardiol. 2004;43:1698–705. doi:10.1016/j.jacc.2003.11.058.PubMedCrossRef

121.

Wu Y, Li Y, Zhang C, A X, Wang Y, Cui W, et al. S100a8/a9 released by CD11b+Gr1+ neutrophils activates cardiac fibroblasts to initiate angiotensin II-induced cardiac inflammation and injury. Hypertens (Dallas, Tex 1979) 2014;63:1241–50. doi:10.1161/HYPERTENSIONAHA.113.02843.

122.

Coletta C, Sestili A, Seccareccia F, Rambaldi R, Ricci R, Galati A, et al. Influence of contractile reserve and inducible ischaemia on left ventricular remodelling after acute myocardial infarction. Heart. 2003;89:1138–43.PubMedPubMedCentralCrossRef

123.

Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution. Eur J Heart Fail. 2016;18:891–975. doi:10.1002/ejhf.592.PubMedCrossRef

124.

Hummel A, Empe K, Dörr M, Felix SB. De novo acute heart failure and acutely decompensated chronic heart failure. Dtsch Arztebl Int. 2015;112:298–310. doi:10.3238/arztebl.2015.0298.PubMedPubMedCentral

125.

Boulogne M, Sadoune M, Launay JM, Baudet M, Cohen-Solal A, Logeart D. Inflammation versus mechanical stretch biomarkers over time in acutely decompensated heart failure with reduced ejection fraction. Int J Cardiol. 2017;226:53–9. doi:10.1016/j.ijcard.2016.10.038.PubMedCrossRef

126.

Oikonomou E, Tousoulis D, Siasos G, Zaromitidou M, Papavassiliou AG, Stefanadis C. The role of inflammation in heart failure: new therapeutic approaches. Hell J Cardiol. 2011;52:30–40.

127.

Heymans S, Hirsch E, Anker SD, Aukrust P, Balligand J-L, Cohen-Tervaert JW, et al. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2009;11:119–29. doi:10.1093/eurjhf/hfn043.PubMedPubMedCentralCrossRef

128.

Dick SA, Epelman S. Chronic heart failure and inflammation: what do we really know? Circ Res. 2016;119:159–76. doi:10.1161/CIRCRESAHA.116.308030.PubMedCrossRef

129.

Grieve DJ, Shah AM. Oxidative stress in heart failure. More than just damage. Eur Heart J. 2003;24:2161–3. doi:10.1016/j.ehj.2003.09.022.PubMedCrossRef

130.

• Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62:263–71. doi:10.1016/j.jacc.2013.02.092. Seminal article proposing a novel paradigm for HFpEF.

131.

Zhi H, Luptak I, Alreja G, Shi J, Guan J, Metes-Kosik N, et al. Effects of direct renin inhibition on myocardial fibrosis and cardiac fibroblast function. PLoS One. 2013;8:e81612. doi:10.1371/journal.pone.0081612.PubMedPubMedCentralCrossRef

132.

•• Martínez-Martínez E, Calvier L, Fernández-Celis A, Rousseau E, Jurado-López R, Rossoni L V., et al. Galectin-3 blockade inhibits cardiac inflammation and fibrosis in experimental hyperaldosteronism and hypertension. Hypertens (Dallas, Tex 1979) 2015;66:767–75. doi:10.1161/HYPERTENSIONAHA.115.05876. Article supporting the potential role of galectin-3 as a therapeutic target in hypertension with excess of aldosterone.

133.

de Boer RA, van der Velde AR, Mueller C, van Veldhuisen DJ, Anker SD, Peacock WF, et al. Galectin-3: a modifiable risk factor in heart failure. Cardiovasc Drugs Ther. 2014;28:237–46. doi:10.1007/s10557-014-6520-2.PubMedCrossRef

134.

van der Velde AR, Gullestad L, Ueland T, Aukrust P, Guo Y, Adourian A, et al. Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. Circ Heart Fail. 2013;6:219–26. doi:10.1161/CIRCHEARTFAILURE.112.000129.PubMedCrossRef

135.

Meijers WC, van der Velde AR, Muller Kobold AC, Dijck-Brouwer J, Wu AH, Jaffe A, et al. Variability of biomarkers in patients with chronic heart failure and healthy controls. Eur J Heart Fail. 2016:1–9. doi:10.1002/ejhf.669.

136.

• de Boer RA, Daniels LB, Maisel AS, Januzzi JL. State of the art: newer biomarkers in heart failure. Eur J Heart Fail. 2015;17:559–69. doi:10.1002/ejhf.273. State-of-the-art review on the current and future role of biomarkers in heart failure management.

137.

van der Velde AR, Meijers WC, de Boer RA. Biomarkers for risk prediction in acute decompensated heart failure. Curr Heart Fail Rep. 2014;11:246–59. doi:10.1007/s11897-014-0207-7.PubMedCrossRef

138.

Lok DJ, Lok SI, Bruggink-André de la Porte PW, Badings E, Lipsic E, van Wijngaarden J, et al. Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res Cardiol. 2013;102:103–10. doi:10.1007/s00392-012-0500-y.PubMedCrossRef

139.

Meijers WC, de Boer RA, van Veldhuisen DJ, Jaarsma T, Hillege HL, Maisel AS, et al. Biomarkers and low risk in heart failure. Data from COACH and TRIUMPH. Eur J Heart Fail. 2015;17:1271–82. doi:10.1002/ejhf.407.PubMedCrossRef

140.

Lepojärvi ES, Piira O-P, Pääkkö E, Lammentausta E, Risteli J, Miettinen JA, et al. Serum PINP, PIIINP, galectin-3, and ST2 as surrogates of myocardial fibrosis and echocardiographic left venticular diastolic filling properties. Front Physiol. 2015;6:200. doi:10.3389/fphys.2015.00200.PubMedPubMedCentralCrossRef

141.

Olimulder MAGM, van Es J, Galjee MA. The importance of cardiac MRI as a diagnostic tool in viral myocarditis-induced cardiomyopathy. Neth Heart J. 2009;17:481–6. doi:10.1007/s12471-010-0007-y.PubMedPubMedCentralCrossRef

142.

Mewton N, Liu CY, Croisille P, Bluemke D, Lima JAC. Assessment of myocardial fibrosis with cardiovascular magnetic resonance. J Am Coll Cardiol. 2011;57:891–903. doi:10.1016/j.jacc.2010.11.013.PubMedCrossRef

143.

Iles L, Pfluger H, Phrommintikul A, Cherayath J, Aksit P, Gupta SN, et al. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J Am Coll Cardiol. 2008;52:1574–80. doi:10.1016/j.jacc.2008.06.049.PubMedCrossRef

144.

•• Papadimitriou L, Smith-Jones PM, Sarwar CMS, Marti CN, Yaddanapudi K, Skopicki HA, et al. Utility of positron emission tomography for drug development for heart failure. Am Heart J. 2016;175:142–52. doi:10.1016/j.ahj.2016.02.016. Molecular imaging, e.g. with PET scanning, holds great promise for early detection, treatment guidance, and other utilities in heart failure management.

145.

Kashiyama N, Miyagawa S, Fukushima S, Kawamura T, Kawamura A, Yoshida S, et al. Development of PET imaging to visualize activated macrophages accumulated in the transplanted iPSc-derived cardiac myocytes of allogeneic origin for detecting the immune rejection of allogeneic cell transplants in mice. PLoS One. 2016;11:e0165748. doi:10.1371/journal.pone.0165748.PubMedPubMedCentralCrossRef

146.

Tarone G, Balligand J-L, Bauersachs J, Clerk A, De Windt L, Heymans S, et al. Targeting myocardial remodelling to develop novel therapies for heart failure: a position paper from the working group on myocardial function of the European Society of Cardiology. Eur J Heart Fail. 2014;16:494–508. doi:10.1002/ejhf.62.PubMedCrossRef

147.

Vanhoutte D, Schellings MWM, Götte M, Swinnen M, Herias V, Wild MK, et al. Increased expression of syndecan-1 protects against cardiac dilatation and dysfunction after myocardial infarction. Circulation. 2007;115:475–82. doi:10.1161/CIRCULATIONAHA.106.644609.PubMedCrossRef

148.

• González GE, Cassaglia P, Noli Truant S, Fernández MM, Wilensky L, Volberg V, et al. Galectin-3 is essential for early wound healing and ventricular remodeling after myocardial infarction in mice. Int J Cardiol. 2014;176:1423–5. doi:10.1016/j.ijcard.2014.08.011. This article describes the potentially adverse effects of early galectin-3 inhibition postmyocardial infarction – it marks the dangers of interfering with early infarct healing.

149.

Mason JW, O’Connell JB, Herskowitz A, Rose NR, McManus BM, Billingham ME, et al. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med. 1995;333:269–75. doi:10.1056/NEJM199508033330501.PubMedCrossRef

150.

Methawasin M, Strom JG, Slater RE, Fernandez V, Saripalli C, Granzier H. Experimentally increasing the compliance of titin through RNA binding motif-20 (RBM20) inhibition improves diastolic function in a mouse model of heart failure with preserved ejection fraction. Circulation. 2016;134:1085–99. doi:10.1161/CIRCULATIONAHA.116.023003.PubMedCrossRef

Title: From Inflammation to Fibrosis—Molecular and Cellular Mechanisms of Myocardial Tissue Remodelling and Perspectives on Differential Treatment Opportunities
Authors: Navin Suthahar
Wouter C. Meijers
Herman H.W. Silljé
Rudolf A. de Boer
Publication date: 01-08-2017
Publisher: Springer US
Published in: Current Heart Failure Reports / Issue 4/2017
Print ISSN: 1546-9530
Electronic ISSN: 1546-9549
DOI: https://doi.org/10.1007/s11897-017-0343-y

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

From Inflammation to Fibrosis—Molecular and Cellular Mechanisms of Myocardial Tissue Remodelling and Perspectives on Differential Treatment Opportunities

Abstract

Purpose of Review

Recent Findings

Summary

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 4/2017

Designing Future Clinical Trials in Heart Failure With Preserved Ejection Fraction: Lessons From TOPCAT

Towards Holistic Heart Failure Management—How to Tackle the Iron Deficiency Epidemic?

Targeting Mitochondrial Calcium Handling and Reactive Oxygen Species in Heart Failure

Novel Biomarkers of Subclinical Cardiac Dysfunction in the General Population

Therapeutic Strategies Targeting Inherited Cardiomyopathies

Impact of Site Selection and Study Conduct on Outcomes in Global Clinical Trials

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page